ZyVersa Therapeutics, Inc. (ZVSA)
| Market Cap | 17.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 9.21M |
| EPS (ttm) | -2.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,800 |
| Open | 2.09 |
| Previous Close | 2.00 |
| Day's Range | 1.90 - 2.09 |
| 52-Week Range | 1.38 - 25.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ZVSA
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida. [Read more]
Financial Performance
Financial StatementsNews
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 35% Today?
ZyVersa Therapeutics (NASDAQ: ZVSA) stock is taking off on Thursday without any recent news from the biopharmaceutical company. Instead, it looks like investors can thank heavy pre-market trading for...
ZyVersa Therapeutics Reports New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTON, Fla., March 13, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treat...
ZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board to Support Clinical Advancement of Renal Cholesterol Efflux Mediator™ VAR 200
WESTON, Fla., March 07, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatmen...
ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference
WESTON, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the t...
ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference
WESTON, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the tr...
ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer's Disease Following Traumatic Brain Injury
WESTON, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatm...
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 94% Today?
ZyVersa Therapeutics (NASDAQ: ZVSA) stock is flying higher on Thursday as investors react to a preliminary prospectus for a stock offering. The stock offering announced by ZyVersa Therapeutics covers...
ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4)
WESTON, Fla., Jan. 27, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatm...
ZyVersa Therapeutics to Present at BIO CEO & Investor Conference
WESTON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the tr...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Wednesday, January 18th at 2:00 PM ET
ZyVersa Therapeutics Appoints Three New Board Members
New appointments bring expertise and proven leadership to ZyVersa to support advancement and development of VAR 200 for renal disease, and IC 100 for inflammatory diseases WESTON, Fla. , Jan. 5, 2023 ...
ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200
Drs. Daniel C. Cattran and Fernando C.
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 41st Annual J.P.
ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates to address significant unmet medical needs of patients with inflammatory and renal diseases Lead anti...
ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA")
ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates for treatment of renal and inflammatory diseases WESTON, Fla. and BRIDGEWATER, N.J.